Phase III Enrollment For Amgen's Panitumumab Slowed By Erbitux Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Enrollment in Amgen's U.S. Phase III trial for the colon cancer agent panitumumab has substantially slowed since the launch of Bristol-Myers Squibb/ImClone's Erbitux (cetuximab)